Clinical Trials Logo

Clinical Trial Summary

This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It study is a multi-center, nonrandomized, open-label, pilot Phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with relapsed or refractory lymphoma.


Clinical Trial Description

PNT2258 will be administered at a dose of 120 mg/m2, as a 3-hour intravenous (IV) infusion on days 1-5 of a 21-day cycle. Treatment may continue (unless there is disease progression or the occurrence of unacceptable toxicity) for a total of 6 cycles of therapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01733238
Study type Interventional
Source Sierra Oncology LLC - a GSK company
Contact
Status Completed
Phase Phase 2
Start date November 2012
Completion date August 2016

See also
  Status Clinical Trial Phase
Terminated NCT00363636 - A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL) Phase 3
Terminated NCT00594308 - In-Vivo Activated T-Cell Depletion to Prevent GVHD N/A
Terminated NCT02518750 - Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Phase 2
Terminated NCT00384150 - Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) Phase 3
Terminated NCT00141700 - Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma Phase 2
Terminated NCT00143884 - Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood Phase 2
Completed NCT02750670 - Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Phase 2
Terminated NCT02473523 - Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia N/A
Completed NCT00413036 - A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma Phase 2
Completed NCT00161590 - Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma Phase 1
Terminated NCT00651443 - Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma Phase 1
Recruiting NCT04756726 - Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma Phase 1/Phase 2
Terminated NCT00395967 - AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone Phase 2
Completed NCT00143871 - Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma Phase 2